纳斯达克 · 生物技术 · USD
Seaport Therapeutics, Inc. (SPTX) 股票分析
Seaport Therapeutics, Inc.（SPTX）是在纳斯达克上市的生物技术股票，以美元交易。
最后更新: 2026年10月21日
价格走势
暂无价格数据
悬停查看每日收盘价。虚线表示区间起始价。
SPTX 关键统计数据
数据截至2026年10月21日交易
- 开盘价
- $19.27
- 前收盘价
- $19.28
- 当日波动区间
- 18.00–20.13
- 52周波动区间
- 14.85–28.38
- 成交量
- 13.46万
估值
- 市值
- $10.56亿
- 市盈率
- 亏损
- 每股收益（近12个月）过去十二个月归属于每股的利润。
- −5.81
财务（财年）
- 营业收入（财年）
- $0.00
- 净利润（财年）
- −$7488.10万
- 流通股数
- 5353.06万
股息与日期
- 财报日期
- 2026年11月12日预计
- 平均成交量
- 19.03万
仅显示公司披露的指标。 数据由Yahoo Finance通过yfinance提供。每日更新。
关键数据
Seaport Therapeutics, Inc.（SPTX）的市值为$10.56亿。
2025财年，SPTX的营业收入为$0.00。
SPTX 各财年营收与利润
财年截至十二月| 财年 | 营业收入 | 净利润 | 净利率 |
|---|---|---|---|
| 2025 | $0.00 | −$7488.10万 | — |
| 2024 | $0.00 | −$4687.90万 | — |
| 财年 | 营业收入 | 毛利 | 营业利润 | 净利润 | 净利率 |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$8729.40万 | −$7488.10万 | — |
| 2024 | $0.00 | — | −$5241.60万 | −$4687.90万 | — |
为公司报告货币口径的年度公布数据。 数据截至2025年12月31日。
最新新闻
Canaccord Genuity Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $28
BenzingaPureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
YahooSeaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
YahooSeaport Therapeutics To Present Phase 1 Clinical Data For GlyphAgo At The European College Of Neuropsychopharmacology Congress, October 10-13
BenzingaHC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target
BenzingaPureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance
Yahoo
全部20篇文章 ↓收起 ↑
Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance
YahooRaymond James Initiates Coverage On Seaport Therapeutics with Strong Buy Rating, Announces Price Target of $46
BenzingaPureTech Health PLC (PTCHF) (H1 2026) Earnings Call Highlights: Cash Runway to 2028, Seaport's ...
YahooSeaport Therapeutics to Participate in September Investor Conferences
YahooHC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target
BenzingaPureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
YahooSeaport Therapeutics, Inc. (SPTX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
SeekingAlphaSeaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
YahooSeaport Therapeutics Reports Phase 1 Results; GlyphAllo At 375 mg Meets Primary Endpoint With No Driving Impairment; 250 mg Dose Also Achieves Key Secondary Endpoint
BenzingaSeaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference
YahooJones Trading Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $32
BenzingaHC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target
BenzingaSeaport Therapeutics: A Development-Arbitrage Platform With Two Layers Of Validation
SeekingAlphaHC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target
Benzinga
新闻由第三方来源提供。不构成投资建议。
分析
数据生成以上所有数字均在每日重新生成时从本页自身的数据中读取。仅供参考，不构成投资建议。 数据截至2026年10月21日。
相关生物技术股票
VRTX
查看所有生物技术股票 →
Vertex Pharmaceuticals Incorporated
$1329.45亿
MRNAModerna, Inc.
$981.36亿
REGNRegeneron Pharmaceuticals, Inc.
$829.48亿
ARGXargenx SE
$559.72亿
ONCBeOne Medicines AG
$439.67亿
RVMDRevolution Medicines, Inc.
$416.41亿
医疗保健热门股票
LLY
查看所有医疗保健股票 →
Eli Lilly and Company
$1.13万亿
JNJJohnson & Johnson
$6212.24亿
ABBVAbbVie Inc.
$5032.75亿
UNHUnitedHealth Group Incorporated
$3742.97亿
MRKMerck & Co., Inc.
$3697.80亿